Ocata Therapeutics Inc fka OCAT

[livingcell]

copied from a board

long on the Yahoo board posted this in the morning, all credit goes
to him: evilpickemking

No new information, but it is nicely written and covers the broader
picture very well.


Link: http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/thread...


Embryonic Stem Cells


To Boldly go where no medicine has gone before.


Almost a year has passed since the inauguration of Barrack Obama. To
those who had seen 8 years of an administration that seemed hell bent
on putting the Kibosh on a science with the potential to not just
treat but to cure a variety of afflictions it was a time of hope. Just
three days after being sworn in as Commander and Chief the first
embryonic stem cell trial was approved by the FDA. Geron's permission
to conduct a landmark study for spinal injuries sent feelings of
elation throughout the scientific community as well as those seeking
treatment from Alzheimer's to Zollinger-Elison Syndrome.


We were brought back to reality when the realization set in that this
was just the beginning of the journey.. With 2 wars in progress and a
country in financial distress those who so desperately anticipated
moving forward with this revolutionary technology would once again
find themselves frustrated. It took two months (March 9th) for the
President to lift the ban on federally funding embryonic stem cells .
A sigh of relief was felt the day the 8 year ban was lifted. A feeling
that would be short lived when it became apparent that hands of
researchers were still bound by the Dickey Wicker appropriation bill
rider. The tortoise like pace of a country engulfed in bureaucracy
veered it's ugly head from the shell. Another blow came when the Geron
trial was halted in August.


Those who held an ethnocentric view of the United States were
dumbfounded as the watched the global race to find cures leave them in
the dust. Belgium, China, India,too many to mention. Many smart US
companies sought a presence outside of America. StemCells Inc.
acquired Stem cell sciences plc. A European company that also had a
base in Australia. They for the first time began to work with
embryonic stem cells.A step that this adult stem cell company was
reluctant to do under the Bush administration and Dr. Andrew Von
Eschenburgh at the helm of the FDA. The presence in Europe gives them
an opportunity to conduct trials both in Europe and in the United
States.


Much has transpired throughout the past year. Obama dismissed his
predecessor's Presidents US council on Bioethics and replaced it with
a new Presidential Commission for the Study of Bioethical Issues. The
final NIH Guidelines for Human Stem Cell Research became effective on
July 7.
On Dec. 2nd The U.S. government approved the first 13 batches of human
embryonic stem cells . It's apparent we are on the road to a more open
minded approach to stem cell research. Not fast enough for those
hungry for cures. Treading carefully however is the prudent. Gerons
trials could start late 2010 as it continues to do further preclinical
studies. The last thing this science needs is it's first trial to
start off with the formation of cysts that had formed in some of their
preclinical studies.


-------------------------------


However, another company could perhaps potentially be the first ESC
trial to actually commence trials. Advanced Cell Technology is that
company . Chief Science Officer Dr. Robert Lanza is world renowned as
a top authority on stem cell research. The company filed an
Investigational New Drug application for Stargardts Maular Dystrophy.
A brilliant move considering the fact that there is a currently no
treatment for the disease. In an interview with BioWorld shortly after
Geron's trial was initially approved Lanza expressed his concern that
the first trial being successful was important to the science in
general. He also explained the significance of choosing an eye disease
because it is an immune privileged site. He was also quoted saying "
Sometimes ,It's the second mouse that gets the cheese."
.


Advanced Cell Technology (ACTC) owns or licenses over 380 patents or
patent applications related to stem cell therapy. Their Myoblast
Program has clearance from the FDA to begin Phase 2 human clinical
trials. They are involved in a joint venture with a leading Korean
biotech.They plan to file an additional IND in the 2nd half of 2010.
In an Era that may go down in US history as the dark ages of science
the company fell into deep financial trouble struggling just to keep
water in the pipettes. Amazingly they persevered fighting tooth and
nail to pull themselves from the precipice. Now nearly a year since
Obama took office they stand to perhaps catapult to the a position of
greatness in the regenerative medicine field.


The company has embryonic stem cell lines pending review with the NIH.
It has also become very obvoius the big pharmaceutical companies have
taken notice of stem cell research. Pfizer recently struck a deal with
Athersys for potentially 105 million. Investing in stem cell science
could prove lucrative. The astonishing part of this story is that
advanced cell technology is currently trading just a smidge above 10
cents. Imagine the possibilities.
A child destined to live with deteriorating eyesight has a chance of
growing up a normal child. A hard working middle-class investor gets
to retire early .


Make no mistake, we stand at the brink of a revolution.

...